{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Journey Medical Corp. Hits New 52-Week High of $9.40
Journey Medical Corp. achieved a new 52-week high of USD 9.40 on November 12, 2025, reflecting a significant increase from its low of USD 3.54. With a market cap of USD 184 million, the company has a low debt-to-equity ratio but is currently loss-making and does not offer dividends.
Journey Medical Corp. Hits New 52-Week High of $9.38
Journey Medical Corp. achieved a new 52-week high of USD 9.38 on November 11, 2025, reflecting a significant performance increase over the past year. With a market cap of USD 184 million, the company has a low debt-to-equity ratio but is currently operating at a loss.
Journey Medical Corp. Hits New 52-Week High of $9.01
Journey Medical Corp. achieved a new 52-week high of USD 9.01 on November 4, 2025, reflecting a strong one-year performance. The company, with a market cap of USD 184 million, has a negative return on equity and a low debt-to-equity ratio, indicating financial stability amid industry challenges.
Is Journey Medical Corp. technically bullish or bearish?
As of August 29, 2025, Journey Medical Corp. has a mildly bullish technical trend, supported by monthly bullish indicators and strong year-to-date performance of 85.93%, significantly outperforming the S&P 500's 12.22%.
Is Journey Medical Corp. overvalued or undervalued?
As of November 12, 2024, Journey Medical Corp. is considered a risky investment due to its overvaluation and poor financial metrics, including a Price to Book Value of 7.99 and a negative EV to EBITDA ratio of -22.82, despite a strong year-to-date return of 85.93%.
Is Journey Medical Corp. overvalued or undervalued?
As of November 12, 2024, Journey Medical Corp. is considered overvalued and risky due to significant negative financial metrics, including a Price to Book Value of 7.99 and negative EV to EBIT and EV to EBITDA ratios, despite a strong year-to-date return of 63.17% compared to the S&P 500's 2.44%.
Is Journey Medical Corp. technically bullish or bearish?
As of June 11, 2025, Journey Medical Corp. shows a mildly bullish trend supported by monthly indicators, though weekly signals indicate some short-term weakness, suggesting a cautious bullish outlook overall.
What does Journey Medical Corp. do?
Journey Medical Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $13 million and a net loss of $4 million as of March 2025. It has a market cap of $147 million and key metrics indicate it is currently loss-making with no dividend yield.
How big is Journey Medical Corp.?
As of Jun 18, Journey Medical Corp. has a market capitalization of 147.00 million and reported net sales of 56.25 million with a net profit of -8.30 million over the latest four quarters. Shareholder's funds are at 20.07 million, and total assets are 80.24 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
